Having trouble accessing articles? Reset your cache.

Infinity discontinues IPI-504

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) discontinued development of IPI-504 to treat breast cancer based on an

Read the full 158 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE